

The following content was supplied by the authors as supporting material and has not been copy-edited or verified by JBJS.

Table S1. Mean regression coefficients of bone turnover markers, quality of life and functional capacity questionnaire scores and pain VAS according to different independent variables of interest measured using mixed-effect models.

Variables	Multivariate MEM - Regression coefficient (95% confidence interval)								
	CTX-1 ^a	OC ^a	25(OH)D ^a	SF-12 MCS ^β	SF-12 PCS	LEM ^β	DASH ^β	Oswestry ^β	VAS ^β
Intercept	0.278 (0.066-0.492)*	9.78 (-1.13-20.7)	92.4 (67.4-117.4)*	43.29 (35.76-50.82)*	50.01 (42.90-57.12)*	84.15 (54.66-113.65)*	39.53 (16.53-62.53)*	10.92 (-21.34-43.18)	3.07 (1.29-4.85)*
Time									
Baseline	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
3 months	NA	NA	13.2 (9.3-17.1)*	1.43 (0.21-2.66)*	2.85 (1.75-3.95)*	9.72 (6.36-13.08)*	-20.57 (-23.63- -17.51)*	-11.13 (-17.23- -5.02)*	-0.74 (-1.04- -0.43)*
6 months	-0.145 (-0.172- -0.118)*	-3.76 (-5.10- -2.41)*	14.7 (11.0-18.4)*	2.13 (0.95-3.31)*	4.23 (3.17-5.28)*	11.24 (7.95-14.54)*	-26.30 (-29.31- -23.29)*	-13.41 (-19.16- -7.65)*	-0.83 (-1.13- -0.52)*
12 months	-0.134 (-0.160- -0.107)*	NA	13.9 (10.3-17.6)*	2.23 (1.01-3.45)*	5.42 (4.33-6.52)*	14.89 (11.51-18.26)*	-32.21 (-35.31- -29.12)*	-11.57 (-17.75- -5.38)*	-1.05 (-1.39- -0.72)*
18 months	-0.127 (-0.157- -0.097)*	NA	21.0 (17.0-24.9)*	1.54 (0.22-2.85)*	5.56 (4.38-6.74)*	14.06 (10.30-17.83)*	-33.12 (-36.48- -29.76)*	-16.71 (-22.98- -10.45)*	-1.37 (-1.75- -0.99)*
24 months	-0.126 (-0.153- -0.098)*	-4.45 (-5.84- -3.05)*	19.3 (15.4-23.1)*	2.18 (0.93-3.42)*	5.69 (4.58-6.81)*	13.75 (10.16-17.33)*	-34.40 (-37.53- -31.27)*	-16.55 (-22.51- -10.58)*	-1.25 (-1.61- -0.88)*

Abbreviations: (CTX-1) type I collagen C-telopeptide, (MCS) mental component scale, (MEM) mixed-effect model, (NA) not applicable, (OC) osteocalcin, (PCS) physical component scale, (Ref) reference, (VAS) visual analogue scale.

*p-value<0.05

^α Mixed-effect models were adjusted for gender, age, BMI, femoral neck and vertebral BMD, history of prior fragility fracture, exposure to treatment before the incident fracture, type of therapy prescribed at baseline (risedronate, alendronate, injectable), referral at baseline, site of incident fracture (major or minor), the Charlson comorbidity index and the number of medications. The type of therapy prescribed at baseline was not included in the adjusted models for 25(OH)D.

^β Mixed-effect models were adjusted for gender, age, BMI, history of prior fragility fracture, exposure to treatment before the incident fracture, referral at baseline, site of incident fracture (major or minor), the Charlson comorbidity index and the number of medications. The incident fracture site was not included in the adjusted models for functional capacity scores. The MEM analysis for Oswestry scores only included gender and age because of the small sample size.